AIM ImmunoTech Inc is trading 84% down at $0.45 following an extreme dilution-driven selloff tied to its latest capital raise.
- The company announced a $2.65 million registered direct offering and concurrent private placement priced at $0.5189 per share.
- The deal involves issuing over 5.1 million shares plus Class J warrants for up to 10.2 million additional shares, significantly increasing the total share count.
- The massive influx of new equity and potential warrant exercises has placed severe downward pressure on the stock price as investors react to the equity dilution.